Compound
← Compound
Official website →
TMOThermo Fisher Scientific INC.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- TMO
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's re…
IndustryMedical - Diagnostics & Research
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
34.99×
P/B
Price divided by book value
4.59×
EV/EBITDA
Enterprise value divided by operating cash generation
25.66×
EV/Revenue
Enterprise value divided by revenue
6.06×
What the company earns
ROE
Return on shareholders’ equity
13.4%
ROA
Return on all assets
6.2%
Gross margin
What remains after product costs
40.4%
Operating margin
What remains after operating the business
17.7%
Net margin
How much of each revenue unit becomes profit
15.1%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.81
Total debt
Sum of borrowings
$42.55B
Cash
Cash available to cover it
$4.06B
Current ratio
Short-term assets divided by short-term liabilities
1.55
Free cash flow
Cash left after investing
$1.68B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.85
Dividend yield
Trailing 12-month distributions divided by price
0.3%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 44.92B | 42.86B | 42.88B | 44.56B |
| Despesas com vendas e administrativas | -8.99B | -8.45B | -8.6B | -8.73B |
| Pesquisa e desenvolvimento | -1.47B | -1.34B | -1.39B | -1.4B |
| Resultado operacional | 8.39B |
News about TMO
Investing.com · 18 hours ago
DHR vs TMO: valuation spread and pairs trade case
TMO is directly named as one side of the comparison. The supplied material does not provide the size of the valuation difference, the relevant metrics, or the direction of the proposed trade.
Yahoo Finance · 3 days ago
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
The article’s case for a resurgence rests on a sequence: post-COVID normalization and concerns about pharmaceutical funding weighed on recent performance, while recurring revenue and ongoing demand in drug discovery and production are presented as support for renewed growth. The source also reports that 118 hedge fund portfolios held the stock at the end of the second quarter, compared with 115 in the previous quarter. These are the article’s cited arguments and ownership data, not a guarantee of future results.
Yahoo Finance · 4 days ago
Three Analysts, Three Verdicts on Thermo Fisher: Here’s Who the Numbers Favor
Thermo Fisher is the direct subject. The material signals a comparison of analyst assessments based on numerical evidence, but the available headline is insufficient to determine which assessment is favored or what the underlying figures show.
Follow TMO and get agent analysis of what is moving the stock.
Open Compound